Shiffman, Saul
Scholl, Sarah M.
Mao, Jason
Ferguson, Stuart G.
Hedeker, Donald
Tindle, Hilary A.
Funding for this research was provided by:
National Institute on Drug Abuse (R01 DA034629)
Article History
Received: 5 September 2019
Accepted: 27 April 2020
First Online: 12 May 2020
Compliance with ethical standards
:
: At the time of this study and analysis, SS, through Pinney Associates, consulted on tobacco cessation and harm reduction (including nicotine replacement therapy and digital vapor products; by contract, combusted cigarettes are excluded) to Niconovum USA, RJ Reynolds Vapor Company, and RAI Services Company, all subsidiaries of Reynolds American, Inc. and British American Tobacco. Previously, SS consulted to NJOY on e-cigarettes, and to GlaxoSmithKline Consumer Healthcare on smoking cessation medications and treatments, including nicotine gum. Currently, SS and Pinney Associates consult to JUUL Labs on harm reduction. SS holds patents for a novel nicotine gum that is not under commercial development. HAT provided input to Achieve Life Sciences regarding study design for a future possible cessation trial of cytisine, and has led or co-led studies using smoking cessation medication donated by the manufacturer (e.g., Pfizer). SGF has worked as a consultant to GlaxoSmithKline Consumer Healthcare and Chrono Therapeutics on matters relating to smoking cessation, has received researcher-initiated project grant funding, and travel funds, from Pfizer, and has served on an advisory board for Johnson & Johnson. Other authors report no competing interests.